Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

Royal Peptides LLC

Has Royal Peptides LLC received an FDA warning letter? Yes. FDA issued a warning letter dated August 24, 2026 concerning products containing tirzepatide and semaglutide and retatrutide.

Letter facts

Letter date
August 24, 2026 (2026-08-24)
Issuing office
Center for Drug Evaluation and Research (CDER)
Products named
TirzepatideSemaglutideRetatrutideSS-31 (Elamipretide)PT-141TesamorelinBIMORELIN
Violation categories
Unapproved new drugMisbranding

Understanding these violation categories

Unapproved new drug

FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

Factual Violation Summary

FDA says the website review found Tirzepatide, Semaglutide, Retatrutide, SS-31, PT-141, Tesamorelin, and BIMORELIN marketed as unapproved new drugs with drug-intended labeling; introducing them into interstate commerce violates FD&C Act sections 301(d) and 505(a).

Statutory Citations & Specific Allegations

  • Unapproved New Drug Violations

More letters about Retatrutide

Recent FDA warning letters concerning Retatrutide:

Similar violations (Unapproved new drug)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.